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Multi-Objective Optimization Applied to the
Eradication of Persistent Pathogens
Ole Steuernagel,1 Daniel Polani,2
Abstract—In scenarios such as therapeutic modelling or pest
control, one aims to suppress infective agents or maximize
crop yields while minimizing the side-effects of interventions,
such as cost, environmental impact, and toxicity. Here, we
consider the eradication of persistent microbes (e.g. E. coli,
Multiply Resistent Staphylococcus aureus (MRSA-‘superbug’),
Mycobacterium tuberculosis, Pseudomonas aeruginosa) through
medication. Such microbe populations consist of metabolically
active and metabolically inactive (persistent) subpopulations. It
turns out that, for efficient medication strategies, the two goals,
eradication of active bacteria on one hand and eradication of
inactive bacteria on the other, are in conflict. Using multi-
objective optimization, we obtain a survey of the full spectrum
of best solutions. We find that, if treatment time is limited
and the total medication dose is constant, the application of
the medication should be concentrated both at the beginning
and end of the treatment. If the treatment time is increased,
the medication should become increasingly spread out over the
treatment period until it is uniformly spread over the entire
period. The transition between short and long overall treatment
times sees optimal medication strategies clustered into groups.
INTRODUCTION
The problem of bacterial persistence
Not only hibernating mammals or sporing fungi reduce or
stop their metabolic activities, also some microbial organisms
are known to randomly slip into and out of ‘hibernation’:
this is essentially characterized by reduced metabolic activity
and reduced or suspended reproduction. The disadvantage of
reduced population growth, goes hand-in-hand with the advan-
tage of reduced vulnerability to drugs, rendering ‘hibernating’
bacteria persistent in the face of medication treatments [2],
[17], [12], [8], [19]. Bacterial population can therefore consist
of genetically identical active and persister subpopulations.
From a human point of view, be it medical or pest control,
the presence of persisters can have serious consequences.
Bacterial persistence was first observed in Staphylococcus
when in 1944 Bigger [2], [12] noted that penicillin did not
always kill all exposed bacteria although sufficient toxicity
was established. Based on the observation that bacteria sur-
viving penicillin treatment were no less susceptible than their
ancestors, it was concluded that heritable bacterial resistance
was not involved but persistent behaviour could explain such
a finding; this has recently been re-confirmed [2].
Bacterial persistence can occur irrespective of environmen-
tal conditions [2], [17] and is widespread [2], [17], [12],
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[8], [11], [7], [16]. It also appears in viruses, which can
become persistent by integrating into their host’s genome and
suspending production of virus particles, as exemplified by
HIV, herpes, and the bacteriophage lambda.
The tradeoff between the persisters’ growth-
underperformance under benign conditions on one hand,
and the wipeout of all active organisms in the case of
a catastrophe on the other, leads to a small random
subpopulation of persisters individually “bet-hedging” to
switch into a persistent state [9] thus effectively establishing
a “life-insurance” [13], [14]. Persistence can bring a
species “back from the brink”, even when sequences of
sudden catastrophes occur, because, in all likelihood, a
few persisters will have stayed out of harm’s way [14].
It is thus relevant in disease prevention [12] and requires
new treatment regimes [19]. E. coli, MRSA-‘superbug’,
Mycobacterium tuberculosis, and Pseudomonas aeruginosa
show persistence [2], [17], [12], possibly extending to airborne
infectants [11]. Persistence also appears to be important in
ecological scenarios [7], [16] and latent HIV-1 infections [8].
In E. coli, the conversion rate from the active subpopulation
to the persistent form and the reverse rate have been shown
to be independent of environmental factors [2], [12]. In other
words, no sensorial input about the quality of the environment
is used to trigger the conversion from one to the other: here we
only consider this type of persistence. It is an effective strategy
for organisms which face life in environments where sudden
devastating degradation and recovery is an acute possibility
and moreover dispenses with the need to maintain sensors
for surveying the environment – an important advantage for
primitive organisms [14].
Our approach
In this paper we primarily intend to highlight the features
of multi-objective optimization and its applicability to prob-
lems in the life sciences. Our model for the eradication of
persistent pathogens shows that eradication of persisters and
normal pathogens form conflicting objectives which are best
approached using multi-objective optimization. Our model is
not intended to quantitatively represent a specific biological
or clinical system but to investigate the problem in general
terms. Multi-objective optimization [4] has been rarely applied
to problems in the life sciences [15], [10]. It is, however,
becoming clear that the benefits of using multi-objective
optimization in the life sciences could be considerable [10].
We adopt population dynamical models based on coupled
differential equations [2], [17], [13], [14] for the numerical
2study of the behaviour of persistent pathogens exposed to
different medication strategies (we use the terms ‘medication’
and ‘drug’ interchangeably, they stand for the presence of
any hazardous entity killing the pathogens, such as radiation,
chemicals, antibodies, etc.).
We assume that only two subpopulations are present, active
(normal) pathogens that grow at a normal rate, and are
susceptible to the medication, and persisters (such as type II
in reference [2]) that grow more slowly and are less suscep-
tible. We assume that the subpopulations are so large that
discreteness of population sizes can be neglected. we denote
the sizes of the normal and the persistent subpopulations
by the time-dependent functions, n(t) and p(t), respectively.
This continuous description allows us to employ continuous
differential equations (in the ‘deterministic limit’ [13]) which
are readily integrated using a computer.
Initially, we will confirm mathematically that the best
approach to the eradication of non-persistent multiplying
pathogens is their immediate extermination by as strong a
medication dose as possible. Whereas this case is intuitively
easy to understand, matters become much more complicated
when persistence is taken into account.
The slowdown or shutdown of the persisters’ metabolism
protects them from medication. One therefore has to retain
some medication to be administered some time after the first
dose of medication was applied. This helps to exterminate
persistent pathogens that have bypassed the biocidal effects of
the initially given medication and subsequently revert back to
their active state.
For such followup action neither very long waiting times
are allowed, because the surviving active pathogens multiply
and thus hurt the host and replenish the persisters’ reservoir,
nor is immediate followup medication advised; otherwise the
persisters have not had enough time to come out of the
persistent state and so the medication hurts the host more than
the pathogens.
Neither intuitive nor analytical solutions for this problem are
available, we therefore choose a model in which a course of
treatment consists of the administration of N equal units of the
drug (we choose N = 10). The total amount of drug applied
during a course of treatment is fixed. The course of treatment
extends over a fixed time interval, spanning from the initial
time t = 0, of the pathogens’ detection, to the time t = T
when the final outcome of the treatment is evaluated. Within
this interval, times for the individual drug administrations tk,
with (k = 1, ..., N ), are chosen freely. Different medication
scenarios, i.e. the effect of different distributions of the N
administration times {tk} are compared for their effectiveness.
The objective of the treatment is the minimization of the sizes
of the normal, n(T ), and the persistent subpopulation, p(T ),
at the end of the course of treatment.
Although we perform multi-objective optimization we fix
this treatment time, T , beforehand. One can, of course,
generalize our approach to include variable treatment times
as well, thus having to consider three objective variables,
namely, n(T ), p(T ), and T . Then, our problem space would be
three dimensional and the set of best solutions would form a
complicated two-dimensional hypersurface embedded in it: too
rich a system for an introductory treatment of our method. We
thus consider a two-dimensional problem space [n(T ), p(T )]
and the family of best solutions that form a one-dimensional
hypersurface within.
We will, towards the end of this paper consider the gen-
eral trends of our model system’s behaviour when the total
treatment time T is varied as well.
Aside from this simplicity issue, there are two more good
reasons to fix the total treatment time T beforehand.
We assume that cumulative toxicity of the medication is
the major constraint regarding its application (this is rea-
sonable for scenarios, such as radiation therapy, many types
of medication treatments and for agricultural and other such
environmental scenarios). With a cumulative dosage constraint,
medication strategies must not be drawn out too much in
time since the medication becomes overdiluted, see below. We
therefore arrive at a natural upper limit for the total treatment
time T .
If there is no time constraint, and if one makes sure
that the medication does not become overdiluted, drawn out
medication regimes where the medication is administered at
a constant rate throughout the treatment T show the greatest
suppression of n(T ) and p(T ), see Figure 3 below. But this
kind of treatment regime can become unstable due to the
danger of overdilution (see caption of Figure 3 below) and
is also harder to adhere to than treatment regimes of fixed
shorter time.
In light of the fact that imperfect patient adherence to
medication strategies is of considerable concern [1], we thus
conclude that there are the following reasons to consider fixed
total treatment times T : simplicity, safety, and practicality.
The problem space and the Pareto front
Different medication strategies lead to different final results.
When the times at which a medication dose is administered
is continuously changed the outcome changes continuously as
well. Therefore, the problem space consists of a connected area
of feasible solutions outside of which lies the region which
cannot be reached by any feasible solution; because, say,
perfect or near perfect suppression of the pathogens’ numbers
is beyond the eradication power of the medication. An example
in our model would be the origin [n(T ), p(T )] = [0, 0] and
its immediate neighbourhood. This area cannot be reached
because the differential equations used in our model only allow
for exponential suppression of the population, not complete
eradication (on the issue of complete extermination due to
fluctuations see reference [13]).
The most interesting area is the boundary that lies between
feasible and unfeasible solutions for small numbers of n(T )
and p(T ), because it contains the optimal cases of what is
feasible. The boundary can have a complicated shape, see, for
instance, Figs. 10 and 13 of reference [18].
The Pareto front contains all those points of the boundary
for which there are no other points which allow for solu-
tions that are simultaneously better or equal with respect to
all optimization objectives; it only contains ‘non-dominated’
solutions. Since the boundary can have a complicated form,
3the subset of Pareto-optimal points can be discontinuous,
see Figs. 11 (c) and 14 (b) of reference [18]. Typically, a
continuous Pareto front in two dimensions has a shape like
the curve shown in Fig. 2 b below, also, compare Figs. 9, 10
and 13 in reference [18].
In principle, using conventional single-objective optimiza-
tion and changing all available relative weight factors that were
used to combine several objectives artificially into a single
one allows us to find the Pareto front as well [18]. How-
ever, for practical reasons this modification of single-objective
optimization is unfeasible because many solutions are being
entirely missed, see Fig. 14 (c) of reference [18]. Using multi-
objective optimization allows us to gain the advantage of being
able to explore the entire set of optimal solutions [18].
Our model
For transparency we also employ the following simplifica-
tions:
The active subpopulation, n(t), grows at a constant rate µn
leading to exponential growth, whereas the persisting sub-
population, p(t), grows at a substantially lower rate µp [13]
which we set to zero for simplicity (without affecting our basic
conclusions). We, similarly, neglect the (greatly reduced) kill
rate of persisters in the presence of medication [2], [13].
The subpopulations convert into each other at constant
rates a and b [2], [13], although these rates may depend
on environmental conditions [9]. We assume that only the
active subpopulation is being decimated by the medication:
we assume its power to kill to be proportional to the drug
concentration, c(t), [3] (although non-linear threshold be-
haviour has been observed as well [3] – in which case other
assumptions such as zero growth of the persisters may have
to be reviewed). We therefore arrive at the following system
of coupled ordinary differential equations for the behaviour of
the subpopulations as functions of time
dn(t)
dt
= (µn − c(t)− a) · n(t) + b · p(t) , (1)
d p(t)
dt
= a · n(t)− b · p(t) . (2)
Our assumptions
In what follows we will assume that the total administered
medication dose is fixed. This assumption is motivated by the
cumulative toxicity of medical treatments. Our approach can
be adapted accordingly, if avoidance of peak values of the drug
concentration is the primary concern.
In general the concentration of the drug, c(t), could be given
by any nonnegative function. In accord with our approach
we model each administered drug dose by the same Gaussian
peaks (bell-shaped curves) with equal strength D0, centered
on the respective administration times tk, a treatment course,
D(t), is thus described by the sum
D(t) =
N∑
k=1
D0
exp
[
−(t−tk)
2
σ2
]
√
πσ
. (3)
Here σ scales the widths of the Gaussians (compare Fig. 1)
and the normalization factor 1/(
√
πσ) assures that each peak
is of unit strength (∫∞
−∞
dt exp
[
−(t−tk)
2
σ2
]
/(
√
πσ) = 1).
We assume that the drug is cleared out of the system at a
constant rate R (in units of hr−1), its concentration, c(t), thus
obeys the differential equation
d c(t)
dt
= D(t)−R c(t) . (4)
For the drug concentration this yields
c(t) = c0 +
∫ t
0
dτ D(τ) e−R(t−τ) , (5)
with the assumed initial value c0 = 0, i.e. no medication is
present before the treatment starts at time zero. Note that small
values of the drug-clearance rate R lead to prolonged presence
of the medication and thus to a greater cumulative effect since
the accumulated medication dose
C(T ) =
∫ T
0
dt c(t) (6)
scales with R−1, just like the total integrated dose
C∞
.
=
∫ ∞
−∞
dt
∫ t
−∞
dτ D(τ)e−R(t−τ) = N D0 /R . (7)
This expression C∞ ignores the initial value assumption
c0 = 0 and therefore has a simple and transparent form.
Because it includes the small tails of the medication distri-
bution extending beyond of the treatment time interval [0, T ]
it slightly overestimates the value of the total cumulative
administered dose, C(T ).
Scenarios that can be described by eqs. (1) and (2) include
a bacterial infection by a persistent species which is being
fought with drugs (term ‘−c(t)·n(t)’ in eq. (4)) where the drug
degrades over time (say, by excretion, aging, or evaporation:
term ‘e−R(t−τ)’ in eq. (7)).
Note that our assumption regarding a finite number of
administered doses N , in eq. (3), is the generic way in which
medication is released (in radiation treatment or pest control
with agricultural aircraft, continuous administration may be
altogether unfeasible). Continuous medication (drip-feed) can
easily be emulated with our model using a large number, N ,
of doses shots.
Without medication (c(t) = 0) the system (1)-(2) has
constant coefficients and is therefore analytically solvable
with the general solution [n(t), p(t)] = w+~e+ exp[λ+t] +
w−~e− exp[λ−t]. Here, the two eigenvector ~e± = [µn − a +
b ±
√
(a+ b)2 + µn(µn − 2a+ 2b), 2a] are associated with
eigenvalues λ± = [bµn ±
√
b2µ2n + 4(µn − b− a)]/2. The
component w+~e+ will quickly outgrow its counterpart w−~e−
because λ+ > λ−. The wild-type without the influence of
medication is therefore typically well described by the state
w+~e+ exp[λ+t]. This implies that the generic initial ratio of
active to persistent pathogens is given by the ratio of the
components of the wild-type ~e+, namely
n(0)
p(0)
=
µn + b− a+
√
(b+ a)2 + 2µn(b− a) + µ2n
2a
. (8)
4We therefore choose n(0) = 1 and p(0) in accordance with
eq. (8) as a natural initial condition which models pathogens
found in their natural infection habitat. If they are found under
very different circumstances, such as bacteria residing in a
bacterial biofilm, the initial fraction of persisters can be much
higher [12] than assumed here.
RESULTS
Equations (1) and (2) do not, in general, allow for an ana-
lytical solution. This is why we investigate them numerically.
A typical scenario is portrayed in Figure 1. It illustrates that
active organisms, n(t), primarily get killed by the medication
whereas the inactive ones, p(t), primarily suffer losses due
to conversion into active ones and regain numbers when the
active ones recover. The two subpopulations sustain each other.
The goal is to push the entire pathogen population towards
its possible extinction (i.e. to such small numbers that action
of the host’s immune system or random fluctuations can wipe
it out [13]).
Fighting non-persistent pathogens
Without persistence all pathogens are affected by the med-
ication and should be killed immediately. This can be shown
formally: assuming the infection is discovered at time zero,
an integration of eq. (1) yields n(T ) = n(0) exp[∫ T0 (µn −
c(τ))dτ ] = n(0) · eE(T ), where the effective exponent
E(T ) = µn · T − C(T ) (9)
contains the accumulated medicine dose, C(t), of eq. (6).
Maximal suppression of the pathogen population requires the
largest achievable negative values of E(T ): the positive growth
term ‘µn ·T ’ has to be minimized. This shows the medication
has to be given immediately.
The effective exponent also yields the condition, E(T ) = 0,
which estimates where the medication just balances pathogen
growth. Assuming, as above, that C(T ) ≈ C∞, we find that
for values of T surpassing
Tmax =
ND0
µnR
, (10)
E(T ) becomes positive and pathogen growth is no longer
kept in check. A fixed total dosage C∞ thus implies a natural
constraint on the total treatment time beyond which drug
overdilution renders treatments ineffective.
Fighting persistent pathogens: Pareto Front
Transition into and out of the persistent state (a, b > 0)
allows pathogens to avoid the effects of medication and
shortens the effective maximal stalemate-time considerably,
thus our estimate for Tmax, derived for the case of non-
persisting pathogens, only establishes an upper bound on the
permissable total treatment time for an effective treatment of
persisters.
Due to their persistence (a, b > 0) pathogens show a
delayed response [2] (compare Fig. 1) which complicates their
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Fig. 1. Response of pathogen population to medication. a,
drug concentration, c(t), as a function of time. N = 7 dose
units, of strength D0 = 430 each, are administered at times
1, 1.5, 2, 4, 4.5, 5, 8 (hours). The widths of the peaks is σ = 0.2 h
and the drug-clearance rate is R = 2h−1. b, The time evolution
of active organisms n(t) (red solid line) and persisters p(t) (blue
dotted line) with parameters µn = 20h−1, a = 0.5 h−1 and
b = 0.5 h−1, note that the persister responses are delayed in
time.
eradication. We now compare different eradication strategies.
First, values for D0 and R (keeping the total effective dose C∞
constant), and a fixed total treatment time T are chosen.
Then we vary the (ten) medication times ({tk}, k = 1, ..., 10)
thus modifying the dosage strategies (choice of time-points
tk ∈ [0, T ] in eq. (3)). Upon integration of equations (1)
and (2), using the fourth order Runge-Kutta method, we
determine the number of survivors n(T ) and p(T ) as our
quality criterion.
The delayed response leads to a tradeoff between eradication
of active versus persister subpopulations, this complicates
the analysis; without further assumptions a best treatment
strategy cannot be identified. To map out the solution space,
we therefore perform multi-objective optimization [4], using
the NSGA-II genetic algorithm [6]. We determine the set
of Pareto-optimal strategies: in an n(T )-over-p(T ) plot they
5form a Pareto-optimal front [4] of points corresponding to
dosage strategies that lead to simultaneously minimized (non-
dominated) final values of n(T ) and p(T ).
For the integration of the differential equation, we use a
regular fourth-order Runge-Kutta integrator, with a step length
of ∆t = 0.01. The integration was found to provide consistent
results for all runs up to a step length of at least ∆t = 0.015,
thus ensuring numerical stability of the employed integration
routine.
The NSGA-II multiobjective optimization algorithm [6]
with a population size of 100 was used, running for 500
generations, using the final populations n(T ) and p(T ) as the
two objectives. The objectives were constrained to nonnegative
values to prevent the genetic algorithm from being caught in
spurious numerical instabilities. The algorithm optimized the
medication times {tk} (k = 1 . . . 10 in our case), the crossover
probability was set to 0.9 and the mutation probability to 0.1.
The parameters ηc and ηm for the polynomial distributions
used in the SBX crossover and in the mutation operator [6],
[5] were both set to 16.
The precise choice of these parameters turned out to be
uncritical. We found that the results reported below are robust
with respect to variations of crossover and mutation probabil-
ities from 0.01 to 0.99, similarly the ηc and ηm parameters
could be varied between 1.6 and 160 without affecting the
position of the Pareto front. Typically, the essential features of
the Pareto front emerged reproducibly after approximately 50
generations, whereas the remainder of the run served to fine-
tune the precise features of the front and the corresponding
solutions. Only for extreme choices of the parameters, namely
crossover and mutation probabilities equal to 0.01 and very
narrow SBX characteristics, ηc = 160, ηm = 160, was
the extent of the Pareto front covered significantly more
slowly; apart from such extreme choices only insignificant
performance differences could be observed.
We now discuss the features of the solutions in detail:
At one end of the Pareto front one finds the strongest
suppression of persisters, at the other end the strongest sup-
pression of active bacteria, compare Fig. 2 a.
Fig. 2 b shows that a strategy aiming to suppress the persis-
tent subpopulation requires early administering of large doses
of medication. This is due to the fact that the active population
has to be suppressed early on and then some medication has
to be used to hold the persister’s in check that are “waking
up” and become active again. Alternatively, when the primary
strategic aim is the suppression of the active subpopulation or a
mixed strategy, a later application of the bulk of the medication
is advised, although (depending on details) some medication
should also be given at the start (as soon as the infection is
discovered). Associated optimal strategies may therefore be
very different from strategies which aim for uniform constant
exposure to medication, or, from the ‘kill before they multiply’
strategy described above. One should note the emergence of
discrete ‘bands’ of optimal strategies in Fig. 2 b.
Although the relative population suppression factor due to
the medication treatment may be satisfactory in the example
sketched in Fig. 2 a and 3, we are clearly most interested in the
critical cases where (because of cost, toxicity, or other reasons)
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Fig. 2. Typical example of optimal treatment strategies. Treat-
ment time T = 30 h, bacterial parameters of E. coli wildtype [13]
(except for our choice of µp = 0): µn = 2h−1, a = 1.2 ·
10−6 h−1, b = 0.1 h−1. We choose n(0) = 1 and p(0) ≈ 5.714 ·
10−7 in accord with the natural initial condition (8). Medication
parameters D0 = 100, N = 10, σ = 10h and R = 0.2 h−1.
a, The Pareto front of optimal strategies shows the tradeoff
between suppressing active and persister subpopulations. The
response margin for suppressing persisters is relatively much
narrower than that for suppressing active pathogens (the spread
of values on the horizontal coordinate axis is small). b, Same
treatment regimes, plot displays dose number k administered
at time tk over total time t and index m (representing the
solution number - out of 100) of solutions found by the NSGA-II
algorithm sorted with respect to increasing values of surviving
persisters p(t). Note the emergence of distinct steps separating
groups of treatment regimes despite a large value of σ (this
distinction becomes clearer still for smaller values of σ). The
color- and symbol-coding matches subsections of the Pareto
front in a with the treatment regimes displayed in b.
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Fig. 3. A collection of several Pareto fronts for various treatment
times T shows increased effectiveness of longer treatments.
Same parameters as in Figure 2 except for treatment times
ranging from T = 10h, . . . , 500 h, see legend. We observe
breakdown of treatment at T ≈ 600 h (not shown) because
medication becomes too much diluted.
the treatment is in danger of failing. In this context it should
be pointed out that, worryingly, the narrow response margin
of final persister subpopulations p(T ) is a generic feature (see
Fig. 2). We are thus led to consider a variation of the total
treatment time T as well. Fig. 3 displays several Pareto fronts
for different values of T . Each individual front shares the
features displayed in Fig. 2. Overall, there is a trend to more
effective treatments with lengthened treatment time in which
case the medication has to be administered more uniformly
over the entire treatment period. It must not be lengthened
too much though, because the medication would become too
diluted (see discussion leading up to expression (10) above).
DISCUSSION
The overall treatment time T has to be sufficiently long
to kill persisters which are protected by the time lag in the
pathogens’ response dynamics but short enough not to dilute
the medication concentration too much. If short treatment
times can yield sufficient pathogen suppression, the use of
such strategies may well be safer, since they lead us away
from a possible breakdown due to overdilution.
Also, as one shortens T , the characteristics of optimal strate-
gies change: instead of being uniformly distributed over T ,
doses are typically increasingly concentrated at the beginning
and/or end of the treatment time, compare Fig. 2 b. Such
strategies do not only need less time than drawn out therapies,
but they are also simpler to administer. We believe that in
view of widespread problems with patient adherence to long
lasting medication regimens [1] such optimized strategies may
offer relevant alternatives that deviate from current clinical
practice. In this context we would like to point out that these
treatment regimes appear to be quite stable with respect to
small changes in strategy, such as completely concentrating all
medication towards beginning and end of the treatment period.
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Fig. 4. Mutant pathogen infection is incurable by the approach
displayed in Figure 3. A collection of several Pareto-fronts for
various treatment times T (hours), see inset, using the same
parameters as in Figures 2 and 3. This includes use of the
same initial conditions as in the wildtype (which are not the
equilibrium conditions from (8) to allow for comparison); only
a = 10−3 h−1, b = 10−5 h−1 are altered to describe the hipQ-
variant of E. coli instead of its wildtype [13].
In other words, a judiciously dosed two-shot approach, almost
the simplest conceivable strategy, can yield nearly optimal
results, is shorter than a maximally drawn out therapy and
not in danger of failure due to overdilution of the medication.
For sufficiently large medication doses, the qualitative re-
sults reported above also apply to the case of amplified per-
sistence (as is the case for the high persistence (hip) mutants
of E. coli analyzed in Balaban et al. [2]). When persistence
is increased, but a simultaneous increase in medication is
impossible, the results can change dramatically. An eradicable
disease can become unstoppable. To illustrate this point, we
compare the response of the wildtype of E. coli, Fig. 3,
with its highly persistent hipQ-type twin [2], [13] in Fig. 4.
We assume the two to be identical except for their different
persistence rates a and b [13]. Under identical treatment
and initial conditions as for the wildtype, we let the search
algorithm find the modified Pareto-front. Fig. 4 shows that
short, highly concentrated treatments allow us to suppress
the active subpopulation but they are too short to affect the
persisters. For longer treatments, the persisters’ reflux rate
b, back to the normal state, is still too low to deplete them
sufficiently, the pathogen has become untreatable.
When our simplifying assumption that persisters are en-
tirely resistant to medication is modified, in favour of re-
duced susceptibility to medication, an extra term of the form
‘−ω · c(t) · p(t)’ has to be added to the right hand side of
eq. (2). With a reasonable factor of the order of ω ≈ µp/µn
(≈ 0.1 in the case of E. coli [13]), our model still displays
similar generic features for optimal treatments. Regimes still
form groups of distinct strategies, doses for optimal treatment
over intermediate lengths T are still administered early and
late. The greatest difference is due to the greater vulnerability
7of the bacteria (i.e., their smaller overall survival rates).
Finally, for other, different conditions and scenarios, such
as modified toxicity behaviour, nonlinear dose-response [3]
and modified quality criteria, one can also use multi-objective
optimization to explore and map the pertinent optimality
regimes.
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